A new study, funded in part by Komen, has found that platinum-based combination neoadjuvant therapy for triple negative breast cancer Capture(TNBC) and BRCA1/2 mutation-associated breast cancer is well tolerated and produces pathologic responses on par with current therapies using anthracycline and taxanes. Breast cancers that arise from BRCA 1/2 gene mutations are, in part, due to their inability to repair DNA mutations by homologous recombination. This inability to repair DNA mutations is a feature shared by some TNBC and could be why this platinum-based combination neoadjuvent therapy is also effective in TNBC patients. MedPage Today covers the findings.